Amgen on GAUSS-3: Evolocumab Meets LDL-Based Primary End PointsAmgen on GAUSS-3: Evolocumab Meets LDL-Based Primary End Points

Teasing with top-line results, the company says the PCSK9 inhibitor dropped LDL-C vs ezetimibe at 24 weeks in patients intolerant of statins, similar to what was shown in the 12-week GAUSS-2 trial. Heartwire from Medscape
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news